AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

10.390

-0.140-1.33%

Volume:458.82K

Turnover:4.80M

Market Cap:1.31B

PE:9.57

High:10.670

Open:10.450

Low:10.320

Close:10.530

Loading ...

Overview Company News Filings

Neuren Pharmaceuticals FY Net Income AUD 24.2 Million

THOMSON REUTERS

Here are the top 10 ASX 200 shares today

Neuren Pharmaceuticals Partner Posts 97% Surge in Rett Syndrome Drug Sales in 2024; Neuren Shares Up 8%

MT Newswires Live

Neuren Pharmaceuticals' (ASX:NEU) investors will be pleased with their massive 712% return over the last five years

Simply Wall St.

Here are the top 10 ASX 200 shares today

Neuren Receives New US FDA Rare Pediatric Disease Designation for Neurodevelopmental Disorder Drug Candidate; Shares Up 6%

MT Newswires Live

BRIEF-Neuren Pharmaceuticals Gets Rare Pediatric Disease Designation From US FDA

BUZZ-Australia's Neuren Pharmaceuticals climbs to two-week high on US FDA designation

Neuren Pharmaceuticals - Neuren Receives Rare Pediatric Disease Designation From US FDA

THOMSON REUTERS

2 ASX 200 pharmaceutical shares surging on big US news

Neuren's Neurodevelopmental Disorder Drug Candidate Receives US FDA Fast Track Designation; Shares Rise 5%

MT Newswires Live

Neuren Pharmaceuticals Ltd - Fast Track Granted by FDA for Nnz-2591 in Pitt Hopkins

THOMSON REUTERS

Neuren Pharmaceuticals Receives Share of Proceeds From Rare Pediatric Disease Priority Review Voucher Sale

MT Newswires Live

BRIEF-Neuren Pharmaceuticals Says Type C Meeting Granted By US FDA

Neuren set for FDA talks on trial to treat developmental genetic disorders

The Market Herald

Neuren Pharmaceuticals Gets Type C Meeting With FDA for Neurodevelopmental Disorder Drug Candidate

MT Newswires Live

Neuren Pharmaceuticals Ltd - Type C Meeting Granted by US FDA for Phelan-Mcdermid Syndrome

THOMSON REUTERS

A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Simply Wall St.

Now small investors on the ASX can pull off ‘The Big Short’

Neuren Pharmaceuticals Limited's (ASX:NEU) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NEU.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":10.39,"timestamp":1745302320000,"preClose":10.53,"halted":0,"volume":458821,"delay":0,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":109796852,"shares":126063594,"eps":1.086099,"marketStatus":"Not Yet Opened","change":-0.14,"latestTime":"04-22 16:12:00 AEST","open":10.45,"high":10.67,"low":10.32,"amount":4804931,"amplitude":0.033238,"askPrice":10.47,"askSize":2187,"bidPrice":10.38,"bidSize":1285,"shortable":3,"etf":0,"ttmEps":1.086099,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":10.53,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0.4474644419909551,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":109796852,"roa":"34.05%","roe":"49.92%","lyrEps":1.111713,"volumeRatio":0.4474644419909551,"shares":126063594,"dividePrice":0,"high":10.67,"amplitude":0.033238,"preClose":10.53,"low":10.32,"week52Low":8.61,"pbRate":"3.60","psRate":"6.04","week52High":24,"institutionHeld":0,"latestPrice":10.39,"committee":-0.259793,"eps":1.086099,"divideRate":0,"volume":458821,"delay":0,"ttmEps":1.086099,"open":10.45,"prevYearClose":12.5,"prevWeekClose":10.53,"prevMonthClose":11.93,"prevQuarterClose":11.93,"fiveDayClose":9.19,"twentyDayClose":12.55,"sixtyDayClose":14.55},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514318359","title":"Neuren Pharmaceuticals FY Net Income AUD 24.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514318359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514318359?lang=en_us&edition=fundamental","pubTime":"2025-02-28 06:28","pubTimestamp":1740695294,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX3A8BF4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2514406188","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2514406188","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514406188?lang=en_us&edition=fundamental","pubTime":"2025-02-27 14:13","pubTimestamp":1740636810,"startTime":"0","endTime":"0","summary":"ASX investors finally caught another break this Thursday, with the S&P/ASX 200 Index (ASX: XJO) rising for only its second session in the past nine trading days. By the time the markets closed up shop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/27/here-are-the-top-10-asx-200-shares-today-27-february-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["APE.AU","BAP.AU","BK7095","BK7113","BK7089","BK7030","NEU.AU","RHC.AU","BK7112","MPL.AU","BK7504","BK7143","XJO.AU","BK7016","CGF.AU","LTR.AU","BK7508","IRE.AU","BK7096","QAN.AU","BK7503","NHF.AU","BK7086"],"gpt_icon":0},{"id":"2514812798","title":"Neuren Pharmaceuticals Partner Posts 97% Surge in Rett Syndrome Drug Sales in 2024; Neuren Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514812798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514812798?lang=en_us&edition=fundamental","pubTime":"2025-02-27 11:01","pubTimestamp":1740625283,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said its partner Acadia Pharmaceuticals reported 2024 net sales of $348.4 million in the US for its Rett syndrome drug, Daybue, according to a Thursday Australian bourse filing.The figure represents a 97% increase from 2023 and is close to the top end of Acadia's guidance of $340 million to $350 million, the filing said.Acadia, the company's partner for the development and commercialization of the drug, provided a 2025 guidance of between $380 million and $340 million for the US market.The company expects royalties of AU$56.2 million for 2024 and between AU$62 million and AU$67 million for 2025.The company's shares rose 8% in recent Thursday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU"],"gpt_icon":0},{"id":"2514032865","title":"Neuren Pharmaceuticals' (ASX:NEU) investors will be pleased with their massive 712% return over the last five years","url":"https://stock-news.laohu8.com/highlight/detail?id=2514032865","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514032865?lang=en_us&edition=fundamental","pubTime":"2025-02-25 13:18","pubTimestamp":1740460687,"startTime":"0","endTime":"0","summary":"For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock performs well, when investors win, they can win big. Just think about the savvy investors who held Neuren Pharmaceuticals Limited  shares for the last five years, while they gained 712%. And this is just one example of the epic gains achieved by some long term investors. Also pleasing for shareholders was the 12% gain in the last three months. It really delights us to see such great share price performance for investors.So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns.While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuren-pharmaceuticals-asx-neu-investors-051807594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7096","BK7508","NEU.AU","NEU","BK4109"],"gpt_icon":0},{"id":"2513134277","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2513134277","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513134277?lang=en_us&edition=fundamental","pubTime":"2025-02-24 14:14","pubTimestamp":1740377653,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) had a wild start to the week's trading this Monday. Overcoming a big opening loss, it finished 0.14% higher by the closing bell, breaking last week's five-day losing s","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/24/here-are-the-top-10-asx-200-shares-today-24-february-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7089","SEK.AU","SGR.AU","BK7141","NHF.AU","CBA.AU","BK7035","ALL.AU","BK7135","BK7505","ING.AU","ANZ.AU","XJO.AU","NEU.AU","BK7511","BK7148","EVT.AU","BK7508","BK7002","APA.AU","BK7078","BK7096"],"gpt_icon":0},{"id":"2513799917","title":"Neuren Receives New US FDA Rare Pediatric Disease Designation for Neurodevelopmental Disorder Drug Candidate; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513799917","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513799917?lang=en_us&edition=fundamental","pubTime":"2025-02-24 11:26","pubTimestamp":1740367584,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  received rare pediatric disease designation from the US Food and Drug Administration for its neurodevelopmental disorder drug candidate, NNZ-2591, in each of Pitt Hopkins syndrome and Angelman syndrome, according to a Monday filing with the Australian bourse.NNZ-2591 previously received the same designation for Phelan-McDermid syndrome.The Australian pharmaceutical company said it \"may be awarded a priority review voucher  if the Rare Pediatric Disease PRV program is reauthorized by the US Congress and NNZ-2591 receives marketing authorization for any of these indications.\"If awarded, a PRV can be used to obtain a priority review for a different product or sold to another sponsor.Neuren Pharmaceuticals' shares were up past 6% in recent Monday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","BK7096","XJO.AU","BK7508","XKO.AU","NEU.AU"],"gpt_icon":0},{"id":"2513762069","title":"BRIEF-Neuren Pharmaceuticals Gets Rare Pediatric Disease Designation From US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2513762069","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513762069?lang=en_us&edition=fundamental","pubTime":"2025-02-24 09:21","pubTimestamp":1740360101,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Gets Rare Pediatric Disease Designation From US FDAFeb 24 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:NEUREN RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM US FDAFurther company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PD06H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2513976255","title":"BUZZ-Australia's Neuren Pharmaceuticals climbs to two-week high on US FDA designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2513976255","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513976255?lang=en_us&edition=fundamental","pubTime":"2025-02-24 09:05","pubTimestamp":1740359124,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharmaceuticals climbs to two-week high on US FDA designation** Shares of Australia's Neuren Pharmaceuticals NEU.AX rise as much as 6.3% to A$14.100, their highest levels since February 7** Stock on track for its second consecutive session of gains, if trend holds** The drug manufacturer gets rare paediatric disease designation from the U.S. Food and Drug Administration ** Designation for NNZ-2591 in each of Pitt Hopkins syndrome and Angelman syndrome - Neuren ** NNZ-2591 used for treatment of any traumatic brain injury    ** Stock has risen 11.6% so far this year, as of 0054 GMT  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL3N3PF00W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2513630167","title":"Neuren Pharmaceuticals - Neuren Receives Rare Pediatric Disease Designation From US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2513630167","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513630167?lang=en_us&edition=fundamental","pubTime":"2025-02-24 06:20","pubTimestamp":1740349213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250223:nFWN3PD06H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2512476511","title":"2 ASX 200 pharmaceutical shares surging on big US news","url":"https://stock-news.laohu8.com/highlight/detail?id=2512476511","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512476511?lang=en_us&edition=fundamental","pubTime":"2025-02-19 12:02","pubTimestamp":1739937730,"startTime":"0","endTime":"0","summary":"The market may be heading lower today but that hasn't stopped two ASX 200 pharmaceutical shares from charging higher. Let's find out what big news out of the United States is giving them a big boost t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/19/2-asx-200-pharmaceutical-shares-surging-on-big-us-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["NEU.AU","BK7508","CU6.AU","BK7096","BCR"],"gpt_icon":1},{"id":"2512144253","title":"Neuren's Neurodevelopmental Disorder Drug Candidate Receives US FDA Fast Track Designation; Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512144253","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512144253?lang=en_us&edition=fundamental","pubTime":"2025-02-19 11:50","pubTimestamp":1739937010,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said that the US Food and Drug Administration  granted fast track designation to its drug candidate NNZ-2591 used for the potential treatment of Pitt Hopkins syndrome , according to a Tuesday filing with the Australian bourse.PTHS is a rare neurodevelopmental disorder with no approved treatment, the filing said.Shares of the company rose past 5% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK7508","BK4567","BK4104","IE00BYQQ9H92.USD","NEU.AU","IE00B5TLWC47.USD","IE00BFXG0V08.USD","BK7096","BK4585","FAST"],"gpt_icon":0},{"id":"2512630143","title":"Neuren Pharmaceuticals Ltd - Fast Track Granted by FDA for Nnz-2591 in Pitt Hopkins","url":"https://stock-news.laohu8.com/highlight/detail?id=2512630143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512630143?lang=en_us&edition=fundamental","pubTime":"2025-02-19 10:00","pubTimestamp":1739930434,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nFWN3P91AR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2509753856","title":"Neuren Pharmaceuticals Receives Share of Proceeds From Rare Pediatric Disease Priority Review Voucher Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2509753856","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509753856?lang=en_us&edition=fundamental","pubTime":"2025-02-07 10:02","pubTimestamp":1738893755,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  received its one-third share of proceeds from Nasdaq-listed partner Acadia Pharmaceuticals' sale of the rare pediatric disease priority review voucher for $150 million in December 2024, according to a Friday filing with the Australian bourse.The voucher was granted by the US Food and Drug Administration after the approval of Daybue for the treatment of Rett syndrome, the filing said.Rett syndrome is a genetic disorder characterized by loss of mobility in the hands as development slows down.The company is entitled to one-third of the proceeds under its license agreement with Acadia, per the filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2509737674","title":"BRIEF-Neuren Pharmaceuticals Says Type C Meeting Granted By US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2509737674","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509737674?lang=en_us&edition=fundamental","pubTime":"2025-02-07 09:25","pubTimestamp":1738891519,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Says Type C Meeting Granted By US FDAFeb 7 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:TYPE C MEETING GRANTED BY US FDA FOR PHELAN-MCDERMID SYNDROMEFurther company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nFWN3OX1VE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2509182750","title":"Neuren set for FDA talks on trial to treat developmental genetic disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2509182750","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509182750?lang=en_us&edition=fundamental","pubTime":"2025-02-07 07:17","pubTimestamp":1738883820,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  has been granted the chance to talk to the U.S. Food and Drug Administration  about some of the positive indicators that may be expected from its upcoming Phase 3 clinical trial program for a drug to treat multiple childhood genetic conditions.The FDA has granted Neuren a Type C meeting – set for early April 2025 – to explore the efficacy endpoints of the trial program for candidate NNZ-2591.This comes after a Type B End of Phase 2 meeting with the government agency, in which key features of the trial were discussed and agreed to.NNZ-2591 is the company’s second drug candidate, which is in development with a focus on treating some neurodevelopmental disorders. During the Phase 2 clinical trial, it revealed positive results regarding Phelan-McDermid syndrome, Pitt-Hopkins syndrome, and Angelman syndrome.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/neuren-set-for-fda-talks-on-trial-to-treat-developmental-genetic-disorders-2025-02-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2509273327","title":"Neuren Pharmaceuticals Gets Type C Meeting With FDA for Neurodevelopmental Disorder Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2509273327","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509273327?lang=en_us&edition=fundamental","pubTime":"2025-02-07 07:10","pubTimestamp":1738883406,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  was granted a type C Meeting with the US Food and Drug Administration to discuss the primary efficacy endpoints of its phase 3 clinical trial program for a neurodevelopmental disorder drug candidate, the company said in a Friday Australian bourse filing.The drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders and achieved positive results in phase 2 clinical trials in Phelan-McDermid syndrome, Pitt-Hopkins syndrome, and Angelman syndrome, per the filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2509781472","title":"Neuren Pharmaceuticals Ltd -  Type C Meeting Granted by US FDA for Phelan-Mcdermid Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2509781472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509781472?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:15","pubTimestamp":1738876531,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nFWN3OX1VE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2509458992","title":"A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509458992","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509458992?lang=en_us&edition=fundamental","pubTime":"2025-02-06 11:35","pubTimestamp":1738812902,"startTime":"0","endTime":"0","summary":"Key Insights The projected fair value for Neuren Pharmaceuticals is AU$13.55 based on 2 Stage Free Cash Flow to Equity...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/a-look-at-the-fair-value-of-neuren-pharmaceuticals-limited-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","BK7508","DCF","TV","BK4100","BK4109","NEU","NEU.AU","FCF","BK4211"],"gpt_icon":0},{"id":"2508154456","title":"Now small investors on the ASX can pull off ‘The Big Short’","url":"https://stock-news.laohu8.com/highlight/detail?id=2508154456","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508154456?lang=en_us&edition=fundamental","pubTime":"2025-02-03 07:39","pubTimestamp":1738539553,"startTime":"0","endTime":"0","summary":"One of the greatest recent films on share markets was The Big Short which was released in 2015.Starring Steve Carell, it did a fairly good job of explaining how shorting works and in particular how gathering information on the sort of junk property loans that were then being written in the US and collected together in highly rated collateralised debt obligations  helped to bring about the global financial crisis.It also showed how investors such as Michael Burry  and Mark Baum  could dramatically profit from shorting stocks – making money by selling shares and buying them back later at a cheaper price.One potential answer has arrived in the form of a new exchange-traded fund that will actively identify and short ASX-listed companies.Developed by VanEck and known as the VanEck Australian Long Short Complex ETF , the aim of what is effectively a listed hedge fund offering without the high initial investment hurdle is to outperform the ASX 200 by selecting a concentrated portfolio of what","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/The-Big-Short-ASX-ALFA-VanEck.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/The-Big-Short-ASX-ALFA-VanEck.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/small-investors-asx-can-pull-off-the-big-short/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["NEU.AU","ALF.AU","ALFA.AU","JBH.AU","FDN","BK4588","BK7508","BK7096","BK4585","BK7001","BK4550"],"gpt_icon":0},{"id":"2505758190","title":"Neuren Pharmaceuticals Limited's (ASX:NEU) Stock's On An Uptrend: Are Strong Financials Guiding The Market?","url":"https://stock-news.laohu8.com/highlight/detail?id=2505758190","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505758190?lang=en_us&edition=fundamental","pubTime":"2025-01-22 09:02","pubTimestamp":1737507736,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals'  stock is up by a considerable 13% over the past week. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. Particularly, we will be paying attention to Neuren Pharmaceuticals'  ROE today.Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.Return on Equity = Net Profit  ÷ Shareholders' Equity. So, based on the above formula, the ROE for Neuren Pharmaceuticals is:. First thing first, we like that Neuren Pharmaceuticals has an impressive ROE. Additionally, the company's ROE is higher compared to the industry average of 13% which is quite remarkable. Under the circumstances, Neuren Pharmaceuticals' considerable five year net income growth of 81% was to be expected.Neuren Pharmaceuticals doesn't pay","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuren-pharmaceuticals-limiteds-asx-neu-010216939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NEU.AU","BK7508","BK4109","NEU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":95,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[]}}